Evaluating Elevance Health (ELV) After A Strong Recent Share Price Run And Conflicting Valuation Signals

Recent performance context for Elevance Health (ELV)

Without a specific headline event driving today’s action, Elevance Health (ELV) is drawing attention after recent share price moves and fresh fundamental data that give investors more context on the health benefits provider’s current positioning.

The stock is up about 4% over the past week, about 22% over the past month and about 13% over the past 3 months, while the 1-year total return is slightly negative. Year to date, the stock is up about 11%.

Alongside these returns, Elevance Health reports annual revenue of about US$200.4b and net income of about US$5.2b, with both revenue and net income growth rates in the low double digits. That combination of scale and growth is shaping current investor interest.

See our latest analysis for Elevance Health.

For investors, the picture is mixed, with the recent 30 day share price return of about 22% pointing to building momentum, while the 1 year total shareholder return is slightly negative and the 3 year total shareholder return is down about 10%.

If Elevance Health has you rethinking where growth and resilience might show up next in care and coverage, it could be worth scanning 32 healthcare AI stocks

After a strong 30 day run and with an intrinsic value model suggesting a large discount, Elevance Health sits at an interesting crossroads. Is this genuine mispricing, or has the market already accounted for future growth?

Most Popular Narrative: 50% Overvalued

According to the most followed narrative from user NateF, Elevance Health’s fair value sits at about $390.54, slightly below the last close around $392.68. This frames a small premium against a model that already bakes in specific growth and margin assumptions.

Elevance Health offers a compelling growth investment opportunity over the next 1-3 years, with significant potential from Medicare Advantage expansion, value-based care, and innovation in digital health. Despite near-term risks from cost pressures and Medicaid declines, its strong market position, diversified revenue base, and undervaluation compared to peers make it an attractive option for long-term investors seeking growth with moderate risk.

Read the complete narrative.

The core of this narrative leans on earnings growth tied to Medicare Advantage, revenue support from multiple payer segments, and profit margins that the model assumes can hold a firmer line than recent results suggest. It also prices in a future P/E level that sits above where the market has typically placed Elevance Health.

Result: Fair Value of $390.54 (OVERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this hinges on Medicaid pressure easing and medical cost trends stabilising, both of which could move against Elevance and undermine that overvaluation call.

Find out about the key risks to this Elevance Health narrative.

Another view on Elevance Health’s value

While the user narrative suggests Elevance Health is slightly overvalued around $392.68 versus a fair value of $390.54, market multiples tell a different story. The stock trades on a P/E of 16.3x, compared with a peer average of 36.4x and a fair ratio of 31.4x.

That gap implies the market is pricing Elevance Health more cautiously than both peers and the fair ratio. This could signal a margin of safety or it could reflect concern about slower forecast growth. The key question for you is whether that discount looks like risk being priced in or an opportunity being left on the table.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mixed signals in the market and the narratives around Elevance Health, it may be helpful to move quickly and weigh the evidence yourself. To see what the current optimism is based on, review the 4 key rewards

Looking for more investment ideas?

Once you have a view on Elevance Health, do not stop there. Fresh opportunities often sit just outside your current watchlist, waiting for a closer look.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com